You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Under the agreement, NeoGenomics will also make a $25 million equity investment in Inivata with an option to buy the company outright.
The funds will be used to support the molecular diagnostics company's growth strategy and for general corporate purposes, MDxHealth said.
The deals are with institutional investors and more than 1 million American Depositary Shares will be offered at A$1.75 per ADS.
The new Series B investment was made by Northpond Ventures, with previously invested $20 million in the Australian diagnostics company.
Uppsala University spinout Astrego has developed a system to rapidly detect bacterial infection and antibiotic susceptibility in biofluid.
The startup company will use the money to develop its microbial tests and AI-based software for surveillance and prevention of hospital-acquired infections.
Formerly known as Diassess, the Emeryville, California-based startup will use the funding to finance regulatory clearances and early commercialization.
The Australian molecular diagnostics firm will use the funds to accelerate commercial expansion in North America and global markets.
Denka now owns 33.4 percent of PlexBio's shares. PlexBio will use the financing for operations and product development.
The financing will go toward ongoing commercialization of the firm's autoimmune tests and therapeutics promotion business.